Improvement of Migraine Severity and Frequency With Migraineguard ™
NCT ID: NCT04759040
Last Updated: 2021-03-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
120 participants
INTERVENTIONAL
2020-04-01
2020-11-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Chronic Migraines and Neurofdeeback Mindfulness
NCT06342219
Comparative Study of Nutraceuticals vs. Conventional Prophylactic Therapy in the Management of Migraine
NCT07147972
A Combination of Coenzyme Q10, Feverfew and Magnesium for Migraine Prophylaxis : a Prospective Observational Study
NCT02901756
The Efficacy of Neurofeedback Mindfulness in Migraine Management
NCT06342232
Study of MIGRA-ZEN RELIEF PLUS In the Treatment of Chronic Migraine Headache
NCT01135784
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The primary end-point is the severity and the frequency reduction of migraine attacks. The secondary end-points will be the existence of adverse reaction.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MigraineGuard
Active supplement treatment , MigraineGuard capsule containing Coq10 , Magnesium ,Vit B2 , Skullcap Extract , Feverfew Extract , Piperine
Migraineguard
2 Capsules per day for 7 Months
Placebo for MigraineGuard
Placebo capsules non identifiable from Migraineguard capsules were used as control comparator
Migraineguard
2 Capsules per day for 7 Months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Migraineguard
2 Capsules per day for 7 Months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Based on IHS criteria ,are diagnosed with migraine (criteria of the International Classification of Headaches Disorders)
* Individuals with minimum of 3 severe to extreme migraine attacks during the last 3 months .
* Generally in good health
Exclusion Criteria
* Excessive usage of painkillers
* Cancer \& Head injury and trauma
* Any medical condition that may impact the validity of collected information
* Previous usage of Botox within 6 months of study
* Last week usage of triptans
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Herbacure Natural
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AMIR A DOWLATSHAHI, PHD
Role: STUDY_DIRECTOR
HERBACURE NATURAL INC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Herbacure Natural
Burnaby, British Columbia, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MIGRAINEGUARD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.